The Latest Cardiac and Vascular News
Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market1 through the Expansion of Robotic Ecosystem for Endovascular Procedures HINGHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) — Microbot […]
Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D. […]
Miami-based Physician Specializes in Minimally Invasive Treatments for Peripheral Vascular Disease, Cancer, and Other Diseases HINGHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that […]
Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space […]
A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization HINGHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within the interventional radiology community for its LIBERTY® Robotic System, […]
HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to […]
FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical Trial HINGHAM, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review […]
Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced […]
HINGHAM, Mass., March 03, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Microbot Medical Inc. (NASDAQ: MBOT), please note that in the first paragraph the appointment of Eyal Morag, M.D. has been changed to commencing June 2020 and in the fourth paragraph Dr. Morag still currently […]
HINGHAM, Mass., Jan. 15, 2019 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into a definitive agreement with an institutional investor for the purchase of 455,323 shares of its […]
